PT  - JOURNAL ARTICLE
AU  - Reed, Sophie
AU  - Diamond, Charlie
AU  - Mahmood, Samiya
AU  - Rymell, Soubera
AU  - Smith, Michael
AU  - Pansini, Michele
AU  - Psaila, Bethan
AU  - Mead, Adam J.
AU  - Thomaides-Brears, Helena
AU  - Chowdhury, Onima
TI  - Multiparametric MRI detects multi-organ impairment in patients with chronic myeloid neoplasms with normal serum biomarkers
AID  - 10.1101/2023.11.23.23298558
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.23.23298558
4099  - http://medrxiv.org/content/early/2023/11/23/2023.11.23.23298558.short
4100  - http://medrxiv.org/content/early/2023/11/23/2023.11.23.23298558.full
AB  - Assessment of organ impairment in patients with chronic myeloid neoplasms is pivotal in selecting treatments and for accurate prognostication of patient outcomes. In order to determine the multi-organ health of patients with chronic myeloid neoplasms, we conducted a prospective, observational study utilising a novel MRI technology which quantitatively assesses the health of multiple organs in one scan. Organ impairment was significantly higher in the patient cohort compared to healthy controls, most notably with increased rates of kidney fibroinflammation 28% vs 0% (p-value = 0.002). MRI-defined kidney impairment was prevalent in patients with normal serum biomarkers of kidney disease, demonstrating the added value of MRI as a tool to identify occult organ impairment. This has wider implications for enhancing the assessment of organ health in patients with a variety of blood cancers at diagnosis and throughout treatment, guiding more personalised strategies and improving patient outcomes.Competing Interest StatementCD: Perspectum Ltd: Current Employment. SR and MP: Perspectum Ltd: Current Employment, Current holder of stock options in a privately-held company. HTB: Perspectum Ltd: Current Employment, Current equity holder in private company, Current holder of stock options in a privately-held company.Funding StatementThe study was supported by the MRC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:HRA and Health and Care Research Wales (HCRW) Approval has been given for the above referenced study. MyeloidScan REC 21/WM/0067.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.